© 2020 MJH Life Sciences and Medical Economics. All rights reserved.
© 2020 MJH Life Sciences™ and Medical Economics. All rights reserved.
November 23, 2020
The company tested two different dosing regimens with one shown to be more effective.
November 20, 2020
The candidate BNT162b2 was shown to be 95 percent effective against COVID-19.
November 18, 2020
BNT162b2 showed 95 percent efficacy against COVID-19.
November 16, 2020
The latest vaccine candidate showed about 95 percent efficacy in a Phase 3 trial.
November 12, 2020
These new codes ensure physicians get paid for keeping their patients safe from COVID-19.
November 09, 2020
The candidate was shown to be more than 90 percent effective in preventing COVID-19 infection.
October 30, 2020
With infections on the rise at the start of flu season, the need for measures to limit transmission is as strong as ever.
October 29, 2020
The interim final rule with comment period would make the vaccine free to patients on Medicare and on most private health plans.
October 21, 2020
Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.
October 16, 2020
In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.